First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study [0.03%]
一线生物制剂治疗选择对溃疡性结肠炎的临床结局影响显著：来自APPETISER研究的结果
Diari M&#x;Baye,Marianne Hupé,Marie Dodel et al.
Diari M&#x;Baye et al.
Background/aims: We compared the effectiveness of 2 strategies based on the choice of the first biologic owing to either drug efficacy or better acceptability in patients with ulcerative colitis (UC). ...
Association between anti-tumor necrosis factor alpha exposure and new-onset autoimmune diseases in inflammatory bowel disease: a nationwide case-control study in Korea [0.03%]
韩国炎症性肠病患者中抗肿瘤坏死因子α与新发自身免疫性疾病关联的全国病例对照研究
Shin Ju Oh,Ji Eun Kim,Su Jin Jeong et al.
Shin Ju Oh et al.
Background/aims: Autoimmune-related events following anti-tumor necrosis factor alpha (anti-TNF-α) therapy are increasingly reported, but population-level data on new-onset autoimmune disease in inflammatory bowel diseas...
Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study [0.03%]
乌帕替尼治疗炎症性肠病的现实世界有效性和安全性：一项单中心回顾研究
Ji Eun Kim,Yeong Chan Lee,Minjee Kim et al.
Ji Eun Kim et al.
Background/aims: Upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in clinical trials for inflammatory bowel disease (IBD); however, real-world data from Asian populations remain limited. ...
Correction: Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease [0.03%]
纠正：胃肠道、骨骼和肌肉：炎症性肠病的骨肌疏松三联征
Shilpa Sharma
Shilpa Sharma
Published Erratum
Intestinal research. 2026 Jan;24(1):192. DOI:10.5217/ir.2024.00185.e 2026
Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis [0.03%]
vedolizumab维持治疗的意义：真实世界中溃疡性结肠炎患者用药情况的启示
Jung Min Moon
Jung Min Moon
The efficacy of ustekinumab in the management of perianal fistulizing Crohn's disease [0.03%]
乌司奴单抗治疗肛周瘘管性克罗恩病的疗效研究
Hee Seok Moon
Hee Seok Moon
Does the size of the cold snare affect the outcome of cold snare polypectomy in the colon? A KASID prospective multicenter study [0.03%]
冷圈套器大小会影响结肠冷圈套息肉切除术的结局吗？一项KASID前瞻性多中心研究
Seongwoo Choi,Jaeyoung Chun,Geunhyuk Choi et al.
Seongwoo Choi et al.
Background/aims: Cold snare polypectomy (CSP) is recommended for colorectal polyps 8 mm as an independent predictor of complete resection (odds ratio, 3.89; 95% confidence interval, 1.15-13.21; P= 0.029); snare size was ...
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team [0.03%]
中国炎症性肠病研究组(JASID)关于溃疡性结肠炎Janus激酶抑制剂的最佳使用和管理策略的共识意见
Seung Min Hong,Dong Hyun Kim,June Hwa Bae et al.
Seung Min Hong et al.
Janus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents-tofacitinib, filgotinib, and upada...
KASID and Intestinal Research journal: a central academic hub for research of intestinal diseases in the Asia-Pacific region [0.03%]
KASID和肠道研究期刊：亚太地区肠道疾病研究的中心学术平台
Jae Hee Cheon,Hye Kyung Hyun,You Sun Kim et al.
Jae Hee Cheon et al.
Analysis of gut microbiota in super donors for fecal microbiota transplantation and isolated gut commensal bacteria of inhibition against Clostridioides difficile [0.03%]
超级捐赠者肠道微生物组和体外抑制艰难梭菌生长的共生细菌分析
Ki Sung Kang,Gee Hyeun Choi,Yu Jin Kim et al.
Ki Sung Kang et al.
Background/aims: Fecal microbiota transplantation (FMT) is increasingly recognized as an alternative to antibiotics for treating recurrent Clostridioides difficile infection. The success of FMT heavily depends on the appr...